Wednesday, November 18, 2026 Evidence-led medical research news
The First Cohort
Medical research, with the receipts

cancer

70 stories tagged "cancer"

Cancer

After 16 Years of 'Talk to Your Doctor,' the American Cancer Society Tells Men 50 to 69 to Get a PSA Test

Distant-stage prostate cancer is rising 6 percent a year in men 55 and older, and the long screening trials now show deaths prevented. The cancer society moved. The federal task force has not.

Drugs & FDA

FDA Fast-Tracks a J&J Head and Neck Cancer Drug on Tumor Shrinkage, and Its Announcement Names No Confirmatory Trial

Tumors shrank in 42 percent of patients in a 102-person trial with no control arm. The FDA says clinical benefit is unconfirmed and confirmatory studies are required, and its announcement does not name one.

Cancer

The Lymphoma Combination With an 'Acceptable Safety Profile' Lost to Its Control Arm

Some oncologists want second opinions to stop steering patients away from trials. Vinay Prasad answered with venetoclax: in its randomized double-hit lymphoma cohort, estimated two-year survival was 52 percent with the drug and 72 percent without it.

Cancer

Four Children's 'Non-High-Risk' Muscle Cancers Carried the Cell State of the Deadly Kind

Four children whose rhabdomyosarcomas lacked the gene fusion that marks the dangerous form died anyway. Read one cell at a time, their tumors shared a gene-activity state with the high-risk disease.

Cancer

A Glioblastoma 'Breakthrough' in October: Two Cell Lines, One Chip, and a Paper From April

Brain tumor cells grown for a month in thickened fluid moved faster and kept some of the changes, but only in two lab lines, which disagreed with each other, and nothing here has touched a patient.

Cancer

Norway's Own Screening Adviser Ran the Numbers: About One in 86 Screened Women Overdiagnosed

By its own adviser's estimate, Norway's mammography program overdiagnoses about one in 86 screened women, roughly three for every breast cancer death it prevents, while a 58-trial review finds early detection is no reliable stand-in for fewer deaths.

Cancer

Roche's KRAS Pill Beat the Older Drugs on Survival, an Endpoint Lumakras Never Won Against Chemotherapy

Median survival ran 17.7 months on divarasib and 12.0 on a control arm that was nine-tenths Lumakras, a drug whose own confirmatory trial showed no survival edge over chemotherapy.

Nutrition & Food

Of 28 Links Between Everyday Drinks and Mouth Bacteria, Alcohol Claimed 25

A federal study of 5,598 Americans tied alcohol, mostly beer and liquor, to 25 of 28 links between drinks and mouth bacteria. It landed months after the Dietary Guidelines dropped their daily drink limits.

Cancer

Mayo's Pancreatic Cancer AI Also Flags One Cancer-Free Scan in Five

Mayo's REDMOD caught 73 percent of pancreatic cancers on CT scans taken months before diagnosis, nearly double the radiologists' rate. It also flagged about 19 percent of cancer-free scans, and its lead researcher says it has not been tested at deployment prevalence.

Cancer

Compass Plans to File a Biliary Cancer Drug Without the Survival Trial the FDA Asked For

Tovecimig plus chemotherapy shrank more biliary tract tumors than chemotherapy alone, but median survival was 8.9 months against 9.4, and 93.5 percent of the combination arm had grade 3 or worse adverse events. The FDA recommended a survival trial before filing. Compass plans to file anyway.

Nutrition & Food

Cold Cuts and Breakfast Cereal Pulled Opposite Ways in a Giant Colon Cancer Study

In 461,682 Americans, total ultra-processed food showed no link to colorectal cancer. Inside the label, reconstituted meat products tracked with higher risk and packaged bread and cereal with lower, while a federal definition sits under White House review.

Cancer

The Vitamin C Trial That Missed Its Goal and Counted 11 Deaths Against 24

Copenhagen and USC researchers gave 1,000 mg of plain vitamin C a day to people with pre-leukemic blood disorders. The mutant clones grew regardless, but over three years of follow-up 11 patients assigned to the vitamin died, against 24 assigned to placebo.

Cancer

The Number Behind GSK's Rectal Cancer Approval Is 47 Percent, Not 76

Independent reviewers confirmed a year-long complete response in 54 of 116 AZUR-1 patients. GSK's release also carried an exploratory 76 percent. For a narrow slice of rectal cancer patients, the drug may still spare them radiation and surgery.

Drugs & FDA

The FDA Fast-Tracked GSK's Rectal Cancer Drug and Left the Trial's Own Scorecard Out of Its Announcement

Independent reviewers found 47 percent of evaluable AZUR-1 patients held a complete response for a year, the trial's registered endpoint. The FDA's announcement quoted friendlier measures instead.

Investigations

Oven Gloves Bought From a Top Online Retailer Tested 89 Percent Asbestos

A private citizen asked two Italian mineralogists whether a cheap pair of heat-resistant gloves labeled Made in China was asbestos. The lab answered 89 percent chrysotile by weight, and the listing never said so.

Cancer

To Keep Cancer-Fighting Cells Alive, a Sloan Kettering Lab Wants Them to Fight Less Hard

Memorial Sloan Kettering researchers say throttling exhausted T cells with a drug class already used against melanoma may keep them alive longer. So far the evidence comes only from lab and animal models.

Cancer

The Urine Test That Could Retire the Bladder Scope Already Has a Startup Behind It

Stanford's uRARE-seq caught 95 percent of localized bladder cancers in a case-control study and nearly tripled cytology's hit rate. It has not faced a prospective trial, and its lead author holds a stake in the spinout commercializing it.

Metabolic & Weight

The Leucine Trick That Boosts Your Mitochondria Also Shielded Lung Tumor Cells in the Lab

Leucine keeps cells from shredding the import docks on their mitochondria. In lab lung tumor lines rich in leucine's chemical family, the same biology came with resistance to a drug built to starve them.

Cancer

Ketamine Failed Its Only Adequately Powered Cancer-Pain Trial, and Palliative Care Still Reaches for It

Ketamine's one adequately powered trial in advanced cancer pain found no benefit over placebo, more toxicity and worse quality of life. Fourteen years on, a 2026 review still tells clinicians to consider it.

Cancer

Cat Breast Tumors Mirror Ours Genetically, and the Cure Talk Never Left the Dish

Almost 500 pet cats supplied tumors for the first large-scale map of feline cancer genes. Every claim about treating people still rests on cat tissue grown in a lab.

Cancer

Merck and Moderna Say Their Melanoma Vaccine Worked, but Two Months On the Public Still Hasn't Seen by How Much

Merck and Moderna have announced only that their phase 3 met its endpoints. The smaller trial behind the excitement missed the conventional two-sided significance bar, and one bank has modeled a price as high as $475,000 per patient.

Drugs & FDA

FDA's Anktiva Approval for Papillary-Only Bladder Cancer Cites No Papillary-Only Patients

Seventeen months after refusing even to review ImmunityBio's application, the FDA expanded Anktiva's label by extrapolating from carcinoma in situ, and its announcement never mentioned the 80 papillary-only patients the company had actually studied.

Cancer

Cancer Wasting Was Hiding in Two Million Routine Weigh-Ins

At Memorial Sloan Kettering, 48.8% of 59,493 tumor-sequenced cancer patients had at least one cachectic weight-loss episode over about five years. No drug is approved for it, and a French hospital coded it in under 1% of its cancer patients.

Drugs & FDA

Terence Tao Fears a Cancer Cure Nobody Can Explain. The FDA Clears Cancer Drugs That Never Proved They Extend Life.

Terence Tao says he would want a human expert to understand an AI cancer cure before taking it. The oncologist Vinay Prasad says that misses how medicine already works, and the receipts show the cancer drugs worth fearing are the legible ones approved on a shrinking tumor that never proved they help